Switching Long-Term Prophylaxis to Donidalorsen for Hereditary Angioedema: 1-Year OASISplus Results - PubMed
6 hours ago
- #donidalorsen
- #long-term prophylaxis
- #hereditary angioedema
- Donidalorsen is an antisense oligonucleotide designed to reduce plasma prekallikrein in patients with hereditary angioedema (HAE).
- The OASISplus study evaluated the long-term safety and efficacy of donidalorsen in patients switching from long-term prophylactic treatments (LTPs) like lanadelumab, berotralstat, or C1 inhibitor.
- 65 patients enrolled, with 54 completing 1 year of treatment. Donidalorsen reduced HAE attack rates by 67.6% over 52 weeks compared to baseline on prior LTPs.
- Most treatment-emergent adverse events (TEAEs) were mild to moderate, with common ones being injection-site erythema and pruritus (10.9% each).
- Quality of life (AE-QoL) improved by 12.2 points, and 90.4% of patients achieved well-controlled disease (AECT ≥ 10) at Week 52.
- Donidalorsen was well tolerated and improved long-term HAE attack rates, quality of life, and disease control in patients switching from other LTPs.